Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]
Discontinued
Reference number: GID-TA10937
For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency for this indication at this time. This is because the company have decided to focus development and registration of erdafitinib in bladder cancer. Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.